share_log

Guangdong Transtek Medical Electronics (SZSE:300562) Strong Profits May Be Masking Some Underlying Issues

Guangdong Transtek Medical Electronics (SZSE:300562) Strong Profits May Be Masking Some Underlying Issues

廣東創思泰醫療電子(深圳證券交易所代碼:300562)的強勁利潤可能掩蓋了一些潛在問題
Simply Wall St ·  04/01 03:32

Following the solid earnings report from Guangdong Transtek Medical Electronics Co., Ltd (SZSE:300562), the market responded by bidding up the stock price. While the profit numbers were good, our analysis has found some concerning factors that shareholders should be aware of.

繼廣東Transtek醫療電子有限公司(深圳證券交易所股票代碼:300562)發佈穩健的收益報告之後,市場的回應是提高了股價。儘管利潤數字不錯,但我們的分析發現了一些股東應該注意的令人擔憂的因素。

earnings-and-revenue-history
SZSE:300562 Earnings and Revenue History April 1st 2024
SZSE: 300562 2024 年 4 月 1 日的收益和收入歷史記錄

The Impact Of Unusual Items On Profit

不尋常物品對利潤的影響

For anyone who wants to understand Guangdong Transtek Medical Electronics' profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥6.6m worth of unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. Guangdong Transtek Medical Electronics had a rather significant contribution from unusual items relative to its profit to December 2023. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

對於任何想了解廣東Transtek醫療電子在法定數字之外的利潤的人來說,值得注意的是,在過去的十二個月中,從價值660萬元人民幣的不尋常物品中獲得了法定利潤。我們不能否認更高的利潤通常會讓我們感到樂觀,但如果利潤是可持續的,我們更願意這樣做。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。而且,畢竟,這正是會計術語的含義。截至2023年12月,廣東Transtek醫療電子因不尋常的項目對其利潤做出了相當大的貢獻。在其他條件相同的情況下,這可能會使法定利潤成爲衡量潛在盈利能力的不良指導。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On Guangdong Transtek Medical Electronics' Profit Performance

我們對廣東 Transtek 醫療電子盈利表現的看法

As we discussed above, we think the significant positive unusual item makes Guangdong Transtek Medical Electronics' earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Guangdong Transtek Medical Electronics' underlying earnings power is lower than its statutory profit. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. You'd be interested to know, that we found 3 warning signs for Guangdong Transtek Medical Electronics and you'll want to know about these.

正如我們上面討論的那樣,我們認爲,這一重大利好不尋常的項目使廣東Transtek醫療電子的收益無法衡量其潛在盈利能力。因此,我們認爲廣東Transtek醫療電子的潛在盈利能力很可能低於其法定利潤。好的一面是,該公司在去年虧損之後,表現出了足夠的改善,今年實現了盈利。本文的目標是評估我們在多大程度上可以依靠法定收益來反映公司的潛力,但還有很多需要考慮的地方。因此,如果你想更深入地研究這隻股票,那麼考慮它面臨的任何風險至關重要。你可能會有興趣知道,我們發現了廣東Transtek醫療電子的3個警告標誌,你會想知道的。

Today we've zoomed in on a single data point to better understand the nature of Guangdong Transtek Medical Electronics' profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

今天,我們放大了單一數據點,以更好地了解廣東Transtek醫療電子利潤的性質。但是,還有很多其他方法可以讓你對公司的看法。有些人認爲高股本回報率是優質業務的好兆頭。雖然可能需要你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論